Inverness Medical Innovations buys Abbott products
This article was originally published in Clinica
Inverness Medical Innovations has agreed to acquire a line of rapid diagnostics products from Abbott Laboratories. It will pay $56.6m for the Determine/DainaScreen business, which includes tests for hepatitis, HIV and syphilis, and which generated revenues of $23m in 2004. The deal brings Waltham, Massachusetts-based Inverness "a viable platform on which we can solidify our commitment to the Japanese market, said chairman, president and CEO Ron Zwanziger. Abbott will continue to distribute Determine products outside the US for up to 32 months in return for a sales commission. Clinica FILED 1 June 2005 COPYRIGHT T&F Informa UK Ltd 2005
You may also be interested in...
Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.
With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says
As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.